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Neurofibromatosis type 1 (NF1) is a common genetic disorder affecting 1 in 3500 individuals. Patients with NF1
arepredisposed todebilitatingskeletalmanifestations, includingosteopenia/osteoporosisand longbonepseu-
darthrosis (nonunion fracture). Hyperactivationof theRas/mitogen-activated protein kinase (MAPK) pathway in
NF1 is known tounderlie aberrant proliferation anddifferentiation in cell lineages, includingosteoclast progeni-
tors andmesenchymal stem cells (MSCs) also known as osteoblast progenitors (pro-OBLs). Our current study
demonstrates thehyperRas/MAPKasacriticalpathwayunderlying thepathogenesisofNF1-associated fracture
repair deficits. Nf1-deficient pro-OBLs exhibit Ras/MAPK hyperactivation. Introduction of theNF1GTPase acti-
vating-related domain (NF1GAP-related domain) in vitro is sufficient to rescue hyper Ras activity and enhance
osteoblast (OBL) differentiation in Nf12/2 pro-OBLs and NF1 human (h) MSCs cultured from NF1 patients with
skeletal abnormalities, including pseudarthrosis or scoliosis. Pharmacologic inhibition of mitogen-activated
protein kinase kinase (MEK) signaling with PD98059 partially rescues aberrant Erk activation while enhancing
OBL differentiation and expression of OBL markers, osterix and osteocalcin, in Nf1-deficient murine pro-
OBLs. Similarly, MEK inhibition enhancesOBLdifferentiation of hMSCs. In addition, PD98059 rescues aberrant
osteoclastmaturation inNf1haploinsufficient bonemarrowmononuclear cells (BMMNCs). Importantly,MEK in-
hibitor significantly improves fracture healing in an NF1 murine model, Col2.3Cre;Nf1flox/2. Collectively, these
data indicate the Ras/MAPK cascade as a critical pathway in the pathogenesis of bone loss and pseudarthrosis
related toNF1mutations.Thesestudiesprovideevidence for targeting theMAPKpathway to improvebonemass
and treat pseudarthrosis in NF1.
INTRODUCTION
Mutations in NF1 cause neurofibromatosis type 1 (NF1), a
common genetic disorder that affects 1 in 3500 individuals
(1–3). Neurofibromin, the protein encoded by NF1, functions
as a GTPase-activating protein (GAP) for Ras (4). The NF1
GAP-related domain (GRD) is critical for accelerating hydroly-
sis of activeRas-GTP to inactiveRas-GDP(4).Mutations inNF1
result in constitutive activation of Ras and its downstream
signaling axis, which leads to a spectrum of clinical sequelae
stemming from the aberrant growth and differentiation of mul-
tiple cell lineages (3,5–7). Individuals with NF1 are afflicted
with a range of malignant and nonmalignant manifestations
(5–14). Clinical studies have found that individuals with NF1
are at significant risk for both generalized (15–20) and focal
skeletal abnormalities (19,21–23). The most debilitating of
these bone anomalies is pseudarthrosis, which is a pathologic
condition, in which spontaneous fracture occurs with a failure
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to unite across the callus. Often times, patientswith pseudarthro-
sis require amputation of the affected limb following multiple
failed orthopedic interventions in order to allow mobility (24).
Interestingly, 50–90% of patients with pseudarthrosis have
Nf1 mutations (25–28). Treatment options for NF1 patients
with pseudarthrosis remain inadequate due to limited informa-
tion on cellular/molecular mechanisms.
Independent groups have reported severalmurinemodels of
NF1with a spectrum of skeletal deficits, including diminished
bonemass, tibial bowing and delayed fracture healing (29,30).
Defective OBL differentiation has been considered to be the
underlying cellular mechanism (29,30). We have previously
reported that haploinsufficiency of Nf1 results in gain-in
osteoclast differentiation and bone resorptive activity.
These studies imply that gain-in osteoclast functions and
impaired OBL differentiation may collaboratively impact
skeletal manifestation in NF1 patients. Interestingly, a previ-
ous clinical study by Stevenson et al. showed that some NF1
individuals with pseudarthrosis exhibit NF1 nullizygosity in
the microdissected pseudarthrosis tissue while being NF1
haploinsufficient in the peripheral blood (23). Based on
these studies, we recently established two novel murine
models, PeriCre;Nf1flox/2 and Col2.3Cre;Nf1flox/2, in which
MSCs, also known as pro-OBLs, and/or OBLs are nullizygous in
Nf1while being systemically heterozygous in cell types, including
osteoclasts and their progenitors. Thesemice recapitulatemultiple
skeletal deficits of NF1 patients, including reduced bonemass and
tibial fracture nonunion (31).
Increased activation of the Ras/ MAPK pathway in NF1 is
known to underlie aberrant proliferation and differentiation in
multiple cell types, including pro-OBLs (32) and osteoclasts
(33). Pre-clinical studies have demonstrated protective effects
of genetic and pharmacologic inhibition of the MAPK
pathway in NF1-associated juvenile myelomonocytic leukemia
murinemodels (34,35). Staser et al. reported that genetic disrup-
tion of both Erk1 and Erk2 in Nf1-deficient mice abates the de-
velopment of myeloproliferative disease (34). Chang et al.
showed a rescue in the myeloproliferative neoplasm phenotype
by targeting the MAPK pathway using a mitogen-activated
protein kinase kinase (MEK) inhibitor (35). Pharmacologic
MEKinhibition has alsobeen shown to reduceneurofibroma for-
mation in mice and decrease aberrant cellular proliferation in
humanmalignant peripheral nerve sheath tumors cell xenografts
(36). Furthermore, studies have shown that deletion of Erk1
leads to increased bone formation (37–39) and inhibits osteo-
clastogenesis (40). We therefore reasoned that the combined
anti-catabolic and pro-anabolic effects of pharmacologic
MAPK inhibition may augment tibial fracture healing in two
murine models of NF1 pseudarthrosis by both increasing bone
formation and reducing bone erosive activity.
Here,weshowthat applicationof theMEKinhibitor,PD98059,
significantly attenuates the capacity ofNf1+/2 BMMNCs to form
osteoclasts in tissue culturewhile promoting terminalOBLdiffer-
entiation and expression of OBL differentiation markers in Nf1-
deficient pro-OBLs. PD98059 treatment also increases OBL dif-
ferentiation in human MSCs cultured from NF1 patients with
tibial pseudarthrosis or scoliosis. More importantly, in vivo
studies show that administration of PD98059 significantly
improves tibial fracture healing inCol2.3Cre; Nf1flox/2 and Peri-
Cre;Nf1flox/2 mice. Collectively, our results demonstrate that a
hyper Ras/MAPK cascade contributes to bone loss and fracture
nonunion in NF1. This suggests that targeting the MAPK
pathway may be a viable therapeutic option for augmenting
bone healing inNF1-associated pseudarthrosis and other osteope-
nic/osteoporotic diseases.
RESULTS
Increased Erk1/2 phosphorylation at the fracture
sites of Col2.3Cre;Nf1flox/2mice
Previous in vitro studies have suggested that theMAPKpathway
is critical for OBL differentiation and skeletal development
(37,38). To examine the impact of neurofibromin in modulating
Ras/MAPK signaling in vivo, Erk phosphorylation was evalu-
ated in midsagittal histological sections from fractured tibia on
day 28 by immunohistochemical staining (Fig. 1A). A signifi-
cant increase in the percent p44/42 positive cells (p44/42
positive cells/total cells) is observed in the Nf1+/2 and Col2.3-
Cre;Nf1flox/2 tissue sections as compared to sections from WT
mice (Fig. 1B).
Re-expression of the NF1 GRD enhances
Nf12/2 OBL differentiation in vitro
It has previously been shown that Nf1+/2 OBLs exhibit Ras
hyper activation (32). Using Raf-pull down assay, we demon-
strate a gene dose-dependent increase of Ras-GTP activity in
Nf1+/2 and Nf12/2 pro-OBLs when compared withe WT
pro-OBLs (Fig. 2A). In addition, pErk1/2 is elevated in
Nf1+/2 and Nf12/2 pro-OBLs in comparison to WT
pro-OBLs at both the basal levels and following recombinant
human platelet-derived growth factor-BB (PDGF) stimulation.
Furthermore, PD98059 inhibits Erk phosphorylation in WT,
Nf1+/2, and Nf12/2 pro-OBLs (Fig. 2B). To evaluate
whether the elevated Ras activity and Erk1/2 phosphorylation
are responsible for impaired OBL differentiation in Nf12/2
pro-OBLs, we re-expressed the NF1 GRD in Nf12/2
pro-OBLs. OBL differentiation assays reveal a substantial res-
toration of alkaline phosphatase (ALP) expression in Nf12/2
pro-OBLs transduced with NF1 GRD as compared to Nf12/2
pro-OBLs transduced with the MSCV-pac control vector
(Fig. 3A). Ras activity, both at the baseline and after PDGF
stimulation, was reduced after re-expression of NF1 GRD in
Nf12/2 pro-OBLs in comparison to MSCV-pac transduced
Nf12/2 pro-OBLs, which demonstrate persistently elevated
Ras-GTP levels (Fig. 3B).
Pharmacologic MEK inhibition enhances OBL
differentiation and increases osteocalcin and osterix
mRNA expression in Nf12/2 pro-OBLs
We next examined whether PD98059 could improve OBL dif-
ferentiation of WT, Nf1+/2 and Nf12/2 pro-OBLs. A gene
dosage-dependent defect in OBL differentiation is observed in
Nf1+/2 andNf12/2 pro-OBLs as determined byALPexpression
(Fig. 4A). To verify the impact of PD98059 on OBL differenti-
ation, we assessed the expression of OBL differentiation
markers, osterix and osteocalcin. Osterix and osteocalcin
mRNA expression was dramatically diminished in Nf12/2
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pro-OBLs versusWT pro-OBLs at a basal level (Fig. 4B and C).
After PD98059 treatment,Nf12/2 pro-OBLs demonstrate a sig-
nificant increase in mRNA expression of both osterix and osteo-
calcin in comparison to WT pro-OBLs (Fig. 4B and C).
Restoration of osterix and osteocalcin expression in Nf12/2
pro-OBLs following PD98059 treatment is consistent with the
increase in ALP expression in PD98059 treated Nf1-deficient
pro-OBLs, suggesting the important role of MAPK pathway in
impaired Nf1-deficient OBL differentiation.
PD98059 attenuates the aberrant frequency of osteoclast
progenitors and osteoclast maturation of Nf11/2 BMMNCs
Colony-forming unit-macrophage (CFU-M) and osteoclastmat-
uration assays were performed in WT and Nf1+/2 BMMNCs to
evaluate the consequence of Nf1 disruption in macrophage and
osteoclast differentiation. Consistent with our previous study
(33), in comparison to WT, Nf1+/2 BMMNCs exhibit signifi-
cantly elevated numbers of osteoclast progenitors (CFU-M) in
Figure 1.MAPKhyperactivation inCol2.3Cre+;Nf1flox/2 tibiae. (A) Representative histological sections from the tibia fracture site ofWT,Nf1+/2, andCol2.3Cre;
Nf1flox/2mice are shown. Red arrows indicate cells that are p44/42 positive (brown). (B) Quantitative measurement of p44/42-positive cells (p44/42-positive cells/
total cells) is shown. Data are represented as mean+SEM from three individual experiments (∗P, 0.05 forWT versusNf1+/2mice, ∗∗P , 0.01 forNf1+/2 versus
Col2.3Cre; Nf1flox/2mice, ∗∗∗P , 0.001 for WT versus Col2.3Cre; Nf1flox/2mice).
Figure 2. PD98059 inhibits hyperactive Ras/MAPK signaling in Nf12/2 pro-OBLs. (A) Ras activity in WT, Nf1+/2, Nf12/2 pro-OBLs was measured at indicated
time following stimulation with PDGF (20 ng/ml). A representative immunoblot is shown. (B) Phosphorylation of Erk1/2 (p44/42) was measured in WT, Nf1+/2,
Nf12/2 pro-OBLs in response to PDGF stimulation in the presence or absence of PD98059 (100 nM). Data represent one of the four independent results.
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Figure 3. Expression ofNF1GRD promotes OBL differentiation inNf12/2 pro-OBL cultures. (A) OBL differentiation was evaluated by ALP staining after 5 days of
culture inOBLdifferentiationmediumusingWTandNf12/2 pro-OBLs transducedwithMSCV-pac control orMSCV-NF1GRD-pac. Representative high power fields
(20×) of OBL cultureswere used to quantify OBLdifferentiation bymeasuringALP expression relative toWT controls (∗∗P, 0.001 forNF1GRDNf12/2 pro-OBLs
versusWTMSCV-pac, andMSCV-pacNf12/2 pro-OBLs, ∗∗∗P, 0.001 forMSCV-pacNf12/2 pro-OBLs versusMSCV-WT, andNF1GRDNf12/2 pro-OBLs). (B)
Ras activity in Nf12/2 pro-OBLs transduced with either MSCV-pac or NF1GRDwas measured at indicated times following PDGF (20 ng/ml) stimulation.
Figure 4. Pharmacologic MEK inhibition improves OBL differentiation and enhances mRNA expression of OBL differentiation markers. (A) WT, Nf1+/2 and
Nf12/2 pro-OBLswere cultured in OBL differentiatingmedium in the presence or absence of PD98059 (100 nM). OBL differentiation wasmeasured by quantifying
ALP expression from representative photomicrographs (20×). Data reflect three independent experiments (∗P , 0.05 for Nf12/2 pro-OBLs treated with PD98059
versusWTpro-OBLs, ∗∗P , 0.01 forNf1+/2 pro-OBLs treatedwith vehicle versusPD98059 treatedNf1+/2 pro-OBLsandWTpro-OBLs, ∗∗∗P, 0.001 forNf12/2
pro-OBLs treatedwith vehicle versus PD98059). (B) OsterixmRNA expression in untreated versus PD98059 (100 nM) treatedWT andNf12/2 pro-OBLswas deter-
mined by a real-time PCR. Osterix expression, relative to untreatedWT, was quantified in three individual experiments (∗∗∗P, 0.001 for untreatedWT versus un-
treated Nf12/2 pro-OBLs and untreated Nf12/2 pro-OBLs versus PD98059 treated Nf12/2 pro-OBLs). (C) Osteocalcin mRNA expression in untreated versus
PD98059 treated WT and Nf12/2 pro-OBLs was determined by a real-time PCR in five individual experiments. Osteocalcin expression was measured relative to
untreated WT (∗∗∗P , 0.001 for untreated WT versus untreated Nf12/2 pro-OBLs and untreated Nf12/2 pro-OBLs versus PD98059 treated Nf12/2 pro-OBLs).
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methylcellulose colony-forming assays (Fig. 5A) as well as an
increased capacity for osteoclast maturation (Fig. 5B). Import-
antly, pharmacologic inhibition of MEK by PD98059 reduces
CFU-M formation and osteoclast maturation in vitro in Nf1+/2
BMMNCs.
MEK inhibition improves fracture healing in
Col2.3Cre;Nf1flox/2 and PeriCre;Nf1flox/2mice
Given the in vitrodataof themultifaceted abilities ofPD98059 in
the restoration of Nf1-deficient OBL differentiation while at-
tenuating the Nf1+/2 osteoclastogenic capacity, we sought to
further test whether pharmacologic MEK inhibition could
improve the fracture healing in a mouse model of NF1-
associated pseudarthrosis. PD98059 was administered to
Col2.3Cre;Nf1flox/2 mice following tibial fracture via a micro-
osmotic pump (contralateral to fractured tibia), whichmaintains
a constant release of the compound (0.25 mL/h at 10 mg/kg/day)
for a period of 28 days (41). Tibiae fracture healing was moni-
tored weekly by radiographs and quantified at the end of 4
weeks by histologic analysis of the fracture site. Radiographic
quantification of the number of healed fractures, as defined by
complete cortical bridging across the fracture site, has been
shown to be 80% in WT mice infused with a vehicle solution
(31). More importantly, radiograph analysis reveals a 3-fold in-
crease in the percentage of healed fractures in Col2.3Cre;
Nf1flox/2 mice receiving PD98059 (66.7%) in comparison to
Col2.3Cre;Nf1flox/2 mice infused with a vehicle solution
(22%) (Fig. 6A, Table 1). No changes are detected via radiog-
raphy on Days 7 and 14 in both vehicle and PD98059 groups,
whereas twomice in the PD98059 group have complete fracture
healing at Day 21.
Thecellular and structural changeswithin the fracture sites are
histologically evaluated by MacNeal/von Kossa counter stain
(Fig. 6B, a) and tartrate-resistant acid phosphatase (TRACP)
stain (Fig. 6B, b). PD98059-treated Col2.3Cre;Nf1flox/2 mice
exhibit a significant reduction in TRACP-positive osteoclasts
when compared with mice receiving vehicle (Fig. 6C). In con-
trast, a significant increase in the trabecular bone area accompan-
ied with augmentation of tissue mineralization (Fig. 6D) and
increase in the number of OBLs (Fig. 6E) is observed inCol2.3-
Cre;Nf1flox/2 mice that received PD98059 compared with
vehicle controls. These results indicate that inhibition of the
MAPK pathway significantly improves fracture healing in
Col2.3Cre;Nf1flox/2 mice by augmenting OBL bone formation
while inhibiting excessive osteoclast bone resorption.
To verify our findings, we repeated the experiments in a
second NF1 murine model, PeriCre;Nf1flox/2, which have
been shown todevelop similar skeletal phenotypes as theCol2.3-
Cre;Nf1flox/2 model (31). Administration of PD98059 (10 mg/
kg/day) induces comparable improvements in fracture healing
outcome in the PeriCre;Nf1flox/2mouse model (Supplementary
Material, Fig. S1A)as evidencedbyan increase in thepercentage
of healed fractures (Supplementary Material, Fig. S1B), reduc-
tion in osteoclast number and an enhancement in callus mineral-
ization (Supplementary Material, Fig. S1C).
Figure 5. Inhibition of MAPK pathway attenuates frequency of osteoclast progenitors and osteoclast maturation of Nf1+/2 BMMNCs. (A) CFU-M formation was
measured inWT andNf1+/2 BMMNCs followingM-CSF (30 ng/ml) stimulation in the presence of escalating dose of PD98059. Data represent the mean+SEMof
three individual experiments (∗∗P , 0.01 foruntreatedandPD98059 (100 nM) treatedWTversusuntreatedandPD98059 (100 nM) treatedNf1+/2CFU-M, ∗P , 0.05
for PD98059 treated (250 nM, 500 nM) WT versus PD98059-treated (250, 500 nM) Nf1+/2 CFU-M. (B) WT and Nf1+/2 BMMNCs were cultured for 7 days and
stained with TRACP to identify mature osteoclasts. (a) Data represent the mean+SEM of % TRACP-positive area in response to varying concentrations of
PD98059 of three independent experiments (∗∗P , 0.01 for untreatedWT versus untreatedNf1+/2 osteoclasts). (b) Representative photographs (20×) of untreated
and PD98059 (100 nM) treated WT and Nf1+/2 osteoclasts are shown.
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Reintroduction of the NF1 GRD and PD98059
rescues OBL differentiation in NF1 hMSCs
To determine whether the Ras/MAPK signaling pathway is also
impactful in the human system, we generated hMSCs from bone
marrow of NF1 patients with pseudarthrosis or scoliosis
(obtained during surgical procedures). We first examined the
neurofibromin expression in NF1 hMSCs. As shown in Supple-
mentaryMaterial, FigureS2, neurofibromin levels are reduced in
NF1 hMSCs compared with control MSCs derived from donor
bone marrow. We next introduced NF1 GRD or MSCV-pac
into hMSCs cultures established from NF1 patients and evalu-
ated OBL differentiation of hMSCs via an ALP expression
assay. Consistent with murine Nf1-deficient pro-OBLs,
reduced ALP expression is observed in NF1 hMSCs compared
with control MSCs. Transduction of NF1 GRD into NF1
hMSCs substantially restores ALP expression when compared
with the control vector (Fig. 7A). To test whether MEK inhib-
ition restores OBL differentiation in NF1 hMSC cultures, as
seen in the murine system, PD98059 was applied to hMSC cul-
tures containing OBL differentiation media. Analogous to the
results achieved in murine-derived Nf1 nullizygous pro-OBLs,
ALP activity is significantly enhanced in NF1 hMSC cultures
following PD98059 treatment in comparison to vehicle controls
(Fig. 7B). These data indicate that theRas/MAPKpathway plays
an important role in the impaired Nf12/2 OBL differentiation.
DISCUSSION
Pseudarthrosis is a debilitating consequence ofNF1with limited
successful intervention. In the current study,wedemonstrate that
the activated Ras/MAPK pathway plays a prominent role in the
pathogenesis of fracture nonunion in NF1. Targeting with a
MEK inhibitor dramatically increases OBL differentiation and
inhibits osteoclast maturation in vitro, which enhances the frac-
ture healing in vivo in Nf1murine models.
Ras proteins regulate the proliferation, survival, differenti-
ation and cytoskeletal functions ofmany cell lineages, including
cells that are central to bone formation and remodeling (42–48).
The biochemical output of Ras proteins is tightly regulated by
neurofibromin, which functions as a negative regulator of the
cycle between an active Ras-GTP and an inactive Ras-GDP
Figure 6.MEKinhibition promotes tibial fracture-healing inCol2.3Cre; Nf1flox/2mice in vivo. Tibial fractureswere generated forWTandCol2.3Cre;Nf1flox/2mice.
Osmotic pumps containing either vehicle control (PBS) or PD98059were implanted subcutaneously in the contralateral dorsal flank ofCol2.3Cre;Nf1flox/2mice.WT
mice receivedvehicle control (PBS) implants. (A) Showingare representative radiographs acquiredat0, 14,21, 28dayspost-fracture inWTmicewithPBSvehicleand
Col2.3Cre;Nf1flox/2 mice with or without PD98059 (10 mg/kg/day). (B, a) Representative photomicrographs (20×) of MacNeal’s/Von Kossa counter stain shows
accumulation of cartilage and infiltration of marrow cells filling the fracture area in the control pump group. (B, b) Representative photomicrographs (20×) of
TRACP stains are shown. Red area represents TRACP-positive-staining osteoclasts. (C) TRACP-positive osteoclasts to the bone surface ratio (Oc.N/BS) was enum-
eratedas shown (∗∗∗P , 0.01). (D)The ratioof bonevolume/tissue volumewasquantified to calculate percent tissuemineralization (∗∗∗P , 0.01). (E)Thenumberof
OBLs per bone surface (Ob.N/BS) was quantified as shown (∗∗P , 0.01).). Data represent mean+SEM from five mice per treatment group.
Table 1. MEK inhibition improves tibial fracture-healing inCol2.3Cre;Nf1flox/2
mice in vivo
Treatment Vehicle pump PD98059 pump
Healed 2 12
Fractured 9 18
% Healed 22% 66.7%
The percentage of healed fractures after 28 days was determined in mice
receiving the vehicle versus PD98059 treatment. Healed fractures were defined
radiographically by complete periosteal bridging across the fracture site.
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state (43,44). Ras activation regulates OBL differentiation
(42,45,46). In previous studies, we and others have shown that
haploinsufficiency ofNf1 results in a reduction of thematuration
ofOBLs and amodest, but not statistically significant, decline in
skeletal formation (32,49). In the present study,we show that de-
letion of Nf1 in pro-OBLs leads to a reduction in OBL differen-
tiation as evidenced by decreased ALP expression and reduced
mRNA expression of OBL specific markers, osterix and osteo-
calcin. Transduction of the full-length NF1 GRD restores OBL
differentiation in both Nf1-deficient pro-OBLs and NF1 patient
hMSCs. Our study is consistent with a previous study that de-
monstrates an increase in OBL differentiation andmineralization
following adenovirus vector-mediated dominant negative Ras
(Ras (DN)) expression in a wild-type osteoblastic cell line (39).
Ras-GTP recruits the serine-threonine kinase, Raf-1, to the
plasma membrane, which in turn activates a series of down-
stream effectors such as Erks (p44/p42 MAP kinase) (47,50).
The activation of these molecules is important in the extracellu-
lar stimuli induced mitogenic response, including proliferation
and differentiation of OBLs (39,51,52). Kono et al. established
the Erk pathway as a negative regulator ofmatrixmineralization
both in vitro and in vivo (39).Highuchi et al. have shown that the
MAPK pathway negatively regulates the OBL differentiation
and the expression of osteocalcin (53). Consistent with the find-
ings of these studies, we now show that inhibition of hyperactive
MAPK signaling by application of anMEK inhibitor (PD98059)
partially restores Nf1-deficient OBL differentiation evidenced
by increasedALPexpression andmRNAexpression ofOBLdif-
ferentiationmarkers, osterix and osteoclacin.More importantly,
PD98059 treatment restores the OBL differentiation of hMSCs
derived from NF1 patients.
Osteoclasts are specialized cells derived from the myeloid
monocyte–macrophage lineage that successively adhere and
remove bone tissue by resorbing the mineralized matrix. Many
skeletal diseases, in particular diseases with decreased bone
mineral density, occur as a consequence of a skeletal imbalance
that favors bone resorption over bone deposition (54). We have
previously shown that Nf1+/2 myeloid cells are hypersensitive
to M-CSF as evidenced by an increase in CFU-M and
CFU-GM (33). In addition, using a genetic mouse model, we
have recently reported that Erk1 plays a critical role in regulating
osteoclast differentiation and bone resorptive activity using a
genetic murine model (40). In the present study, we show that
pharmacologic inhibition of the MAPK pathway using the
MEK inhibitor, PD98059, inhibits aberrant osteoclast differenti-
ation and maturation. In addition, compared with WT, Nf1+/2
osteoclasts are hypersensitive toMEK inhibition, which demon-
strates the biological relevance of this pathway in mediating
Nf1+/2 osteoclast gain-in-functions.
Schindeler et al. previously showed that the combination of
bisphosphonates with recombinant bone morphogenetic
protein 2 (BMP-2) promotes heterotypic bone formation (55)
and tibial fracture repair (56) inNf1+/2mice.This combinatorial
approach provides insight for targeting both the anabolic and
catabolic pathways of bone remodeling. Kolanczyk et al.
reported that treatment with lovastatin improved bone healing
defects in a Nf1Prx2/2 cortical bone injury model (57). Wang
et al. reported that locally applied lovastatin improved tibial
fracture healing in a Col2.3Cre+;Nf1flox/flox mouse model (29).
By indirectly inhibiting the prenylation of G-proteins including
Ras, lovastatin has generated interest for its potential to modu-
late NF1 molecular defects, although nonspecifically. In the
present study, we use a MEK inhibitor to target downstream
effectors of Ras to restore the aberrant functions of Nf1 mutant
OBLs and osteoclasts. By attenuating hyperactive Ras/MAPK
signaling in Nf1-deficient OBLs and osteoclasts, PD98059
exhibited potent anabolic and anti-catabolic effects on bone re-
modeling within the fracture site, significantly improving tibial
fracture healing in two previously established murine models
of pseudarthrosis associated with NF1.
In summary, our current study demonstrates the pivotal role
Ras cascade likely plays in both OBLs and osteoclasts. We
Figure7. Inhibition ofRas/MAPKsignalingenhancesOBLdifferentiation inNF1hMSCs. (A)Reintroductionof theNF1GRDintoNF1patient hMSCs restoresOBL
differentiation. ALP expression, relative to WT control, is shown (∗∗∗P , 0.001 for MSCV-pac control hMSCs versus MSCV-pac NF1 hMSCs, ∗∗P , 0.01 for
MSCV-pac NF1 hMSCs versus NF1 GRD NF1 hMSCs,). (B) Pharmacologic MEK inhibition (100 nM PD98059) enhances OBL differentiation in NF1 patient
hMSCs (∗P , 0.05 for vehicle-treated NF1 hMSCs versus control hMSCs, and NF1 hMSCs vehicle versus PD98059 -reated NF1 hMSCs. Data are representative
of three NF1 and two control samples.
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show that hyperactiveMAPK signaling is responsible, at least in
part, for the defective OBL differentiation/bone formation and
increased osteoclast maturation in vivo in NF1. This study pro-
vides pre-clinical evidence for targeting MEK components of
the Ras/MAPK pathway, which may have potential therapeutic
value to improve fracture healing in NF1 patients. However,
PD98059 has been shown to have side effects on different
cell lineages (58,59), which requires further testing of clinical-
gradeMAPK inhibitors to determinewhether Ras-MAPK inhib-
ition may be a viable therapeutic strategy to increase bone mass
and decrease bone resorption in NF1 patients with long bone
healing defects.
MATERIALS ANDMETHODS
Animals
Nf1+/2 mice were obtained from Dr Tyler Jacks at the Massa-
chusetts Institute of Technology (Cambridge, MA, USA) (60).
Nf1flox/flox mice were provided by Dr Luis Parada at the Univer-
sity of Texas SouthwesternMedicalCenter (8).Col2.3Cre trans-
genic mice were generated as described elsewhere (61).
Conditional bi-allelic deletion ofNf1 in pre-OBLs was achieved
by genetic intercross of Nf1flox/flox mice with Col2.3Cre+ mice,
placing the Cre gene under the control of the 2.3 kb proximal
fragment of the a1(I)-collagen promoter, which is specifically
expressed in OBLs (62,63). Col2.3Cre+;Nf1flox/2 mice (Nf1
null in OBLs, systemically Nf1 heterozygous) were generated
by intercrossing Col2.3Cre+;Nf1flox/flox mice with Nf1+/2 mice
as described previously (31). PeriCre+ mice were intercrossed
with mice bearing conditional genetic targeting of the Nf1
allele (Nf1flox/flox) to generate PeriCre+;Nf1flox/flox mice (Nf1
null in pro-OBLs and OBLs, systemically WT). Similarly,
PeriCre+;Nf1flox/2mice (Nf1 null in pro-OBLs and OBLs, sys-
temically Nf1 heterozygous) were generated by intercrossing
PeriCre+;Nf1flox/flox mice with Nf1+/2 mice (31). Mice were
born at the expectedMendelian ratio. All studies were approved
by the InstitutionalAnimalCare andUseCommittee. Chemicals
were purchased from Sigma (St. Louis,MO, USA) unless other-
wise stated.
Pro-OBL cell culture
Pro-OBLs were generated from WT, Nf1+/2, and PeriCre+;
Nf1flox/2 mice as previously described (32). Briefly, BMMNCs
were separated by low-density gradient centrifugation from
bone marrow of 6 to 8-week-old mice. BMMNCs were then
resuspended and cultured in mouse MesenCult basal medium
containing MesenCult Supplement (Stem Cell Technologies
Inc., CA, USA) at a concentration of 2 × 106 cells/ml in a
10 cm tissue culture plate. Once the cultures reached 80–90%
confluency, cells were trypsinized and replated at a density of
5 × 105 cells/75 cm2. Pro-OBLs at passage 5–10 were used
for the following experiments.
OBL differentiation assays
Pro-OBLs were cultured in osteogenic differentiation medium,
consisting of MSC complete medium supplemented with
1028 M dexamethasone, 50 ng/ml ascorbic acid and 10 mM
b-galactophosphate. Pro-OBLs underwent differentiation for 5
days in the presence and absence of PD98059 (100 nM)
(64,65). OBL differentiation cultures were processed for ALP
expression using an ALP staining kit (32,66). Cells were then
evaluated microscopically and OBL differentiation was quanti-
fiedbymeasuring the intensity ofALPexpressiondetermined by
ImageJ software (32).
Clonogenic progenitor assays
CFU-MofBMMNCswas assayed, as described previously (33).
Briefly, 2.5 × 104WT and Nf1+/2 BMMNCs were seeded onto
a 35 mmgridded dish containingmethylcellulose supplemented
withmurine recombinantM-CSF (30 ng/ml) andmurine recom-
binant RANKL (20 ng/ml) with or without PD98059 (100 nM)
for 7 days at 378C in a 5% CO2 incubator. Colonies were
scored using an inverted light microscope. M-CSF and
RANKL cytokines were purchased from PeproTech (Rocky
Hills, NC, USA).
Generation of murine osteoclasts and TRACP staining
Mouse osteoclasts were obtained in vitro using BMMNCs, as
described previously (40). Briefly, BMMNCs from 8-week-old
WT and Nf1+/2 mice were isolated by long bone marrow flush
and Ficoll density gradient centrifugation (2400g) and cultured
in alpha-modified minimum essential medium (a-MEM) sup-
plemented with 10% fetal bovine serum (FBS), 30 ng/ml
M-CSF and 20 ng/ml RANKL for 3 days with or without MEK
inhibitor (PD98059). On day four, the cell culture medium was
changed to a-MEM supplemented with 10% FBS, M-CSF
(30 ng/ml) and 60 ng/ml RANKL for another 3 days with or
without PD98059. Osteoclasts were identified by fixation of ad-
herent cells with a solution containing 25 ml citrate solution,
65 ml acetone and 8 ml 3.7% formaldehyde, followed by
TRACP stain using a commercially available kit. Osteoclasts
were visualized with a Nikon TE2000-S microscope (Nikon
Inc.,Melville, NY,USA), and imageswere taken by aQImaging
camera and QCapture-Pro software (Fryer Company Inc., Cin-
cinnati, OH, USA). Multinucleated TRACP-positive-staining
cells containing more than three nuclei were scored as mature
osteoclasts. The area of multinucleated, TRACP-positive osteo-
clasts was normalized to the bone surface area and calculated
(osteoclast area % per field) using ImageJ software (32).
Human MSC culture and OBL differentiation assays
Human samples used in this study were approved by the Indiana
University School of Medicine and University of Utah Institu-
tional Review Boards. Human MSCs (hMSCs) were cultured
from bone marrow aspirates collected from discarded bone
and marrow tissues of healthy controls and NF1 patients under-
going surgical procedures for pseudarthrosis or scoliosis. Cells
were cultured using a MesenCult basal medium containing
MesenCult Supplement (Stem Cell Technologies Inc., CA,
USA) and the medium was changed once a week. Passages 5–
10 were used for experiments. The hMSCs underwent OBL dif-
ferentiation in the medium supplemented with ascorbic acid
(50 ng/ml),b-glycerolphosphotase (10 mM)anddexamethasone
(1028 M) for 5 days with or without PD98059 (100 nM). Cells
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were stained with an ALP staining kit and microscopically
examined to quantifyOBLdifferentiation using the Image J soft-
ware (32). Two normal controls and three NF1 patient samples
were used to conduct the experiments.
Generation of recombinant retroviral plasmids and
retroviral transduction of pro-OBLs and hMSCs
Previously developed recombinant retrovirus constructs were
used in these studies (67). A virus expressing the full-length
NF1 GTPase activating-related domain (NF1 GRD) pac
(MSCV-NF1 GRD-pac) under transcriptional control of the
myeloproliferative sarcoma retrovirus promoter and a virus
expressing the selective marker gene alone (MSCV-pac) under
transcriptional control of a phosphoglycerate kinase promoter
were employed in this study via a viral transduction method-
ology described elsewhere (32). Briefly, pro-OBLs and
hMSCs were cultured in MesenCult media and transduced
with either MSCV-NF1 GRD-pac or MSCV-pac followed by
puromycin-resistant selection (5 mg/ml) beginning 72 h follow-
ing transduction.
Tibial fracture, radiography and osmotic pump
implantation
Asingle tibial fracturewas induced as described previously (31).
To stabilize the bone post-fracture and permit load-bearing, an
intramedullary rod (a 30-G needle) was surgically inserted via
the proximal end of the tibia into the medullary canal to
achieve internal fixation. A fracture was generated between the
middle 1/3 and distal 1/3 of the tibia by dropping a 200 g
weight fromaheight of 30 cm.Toensure standardizationof frac-
tures, radiographs were obtained following the fracture using a
pixRay-100 X-ray scanner (Bioptics, Pheonix, AZ, USA). The
mice were allowed to recover on a heated pad and then placed in
recovery cages. Radiography was performed weekly to monitor
fracture repair, defined by complete cortical bridging across the
fracture site, for a duration of 4 weeks, time course determined
by the previous study (31). In the event where internal fixation
failed (due to pin slippage, bending or breakage), the affected
mouse was euthanized and excluded from subsequent analysis.
For osmotic pump implantation, immediately following frac-
ture, Col2.3Cre;Nf1flox/2 and PeriCre;Nf1flox/2 mice were
implanted with a subcutaneous Alzet 1007D micro-osmotic
pump (Durect, Alzet, Cupertino, CA, USA) under the contralat-
eral dorsal skin under avertin anesthesia. To obtain a constant
release, PD98059 (10 mg/kg/day) (68,69) or vehicle (PBS)
was released over 28 days (31) at a rate of 0.25 ml/h.
Histomorphometric measurements
After euthanasia, tibiaewere dissected from themice andfixed in
10% neutral buffered formalin for 48 h, dehydrated in graded
ethanols, and embedded undecalcified in methylmethacrylate.
Midsagittal sections (4 mm thick) were cut from the tibiae
using a motorized microtome equipped with a tungsten-carbide
knife (Leica Inc, Deerfield, IL, USA). The sections were pro-
cessed with TRACP and MacNeal and/or von Kossa stain for
the identification and enumeration of osteoclasts and OBLs, re-
spectively (31). In addition, immunohistochemical stainingwith
an anti-phosphoErk1/2 antibody (Cell Signaling, Danvers, MA,
USA)wasperformed inpost-fractured, control tibiae todetermine
the activity of Ras/MAPK signaling. The sectionswere imaged at
20× magnification on a Leitz DMRXE microscope (Leica Mik-
roskopie und System GmbH, Wetzlar, Germany) equipped with
a SPOT digital camera (Diagnostic Instruments, Inc., Sterling
Heights, MI, USA).
Western blot and Ras activation assays
Murine pro-OBLswere deprivedof serumandgrowth factors for
24 h. For the stimulation only group, cells were stimulated with
PDGF (20 ng/ml) for 2 min. For the inhibitor group, cells were
pre-inhibited with PD98059 (100 nM) for 30 min, followed by
stimulation with PDGF (20 ng/ml). Cells were lysed in nonionic
lysis buffer (20 mM Tris–Cl, 137 mM NaCl, 1 mM EGTA
(ethylene-glycol-tetra-acetic acid), 1% Triton X-100, 10% gly-
cerol, 1.5 mMMgCl2) containing protease inhibitors (Amersham
Pharmacia Biotech, Piscataway, NJ, USA). The protein concen-
tration of the lysates was normalized using the bicinchoninic
acid assay (BCAassay)kit (Pierce,Rockford, IL,USA).Proteins
were separated by 12.5% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS–PAGE) and trans-
ferred to high-quality polyvinylidene difluoride membranes
(Roche Diagnostics, Indianapolis, IN, USA) in a Tris (20 mM),
glycine (150 mM) and methanol (20%) buffer at 250 mV for
2 h at 48C. After blocking in 5% nonfat dry milk in phosphate
buffered saline tween-20 (PBST), the membranes were incu-
batedwith primary antibodies at 1:1000dilution (phospho-ERK,
total-ERK, b-Actin; Cell Signaling) in 5% milk in PBST over-
night at 48C. Following overnight exposure, the membranes
were washed three times with PBST and incubated with second-
ary antibodies (anti-rabbit, anti-mouse, GE Healthcare UK
Limited, UK) conjugated with horseradish peroxidase at
1:5000 dilution in 5%milk in PBST for 1 h at room temperature.
Membranes were washed again in PBST three times at room
temperature. Membranes were exposed to a supersignal west
pico chemiluminescent substrate (Thermo Scientific, Rockford,
IL, USA) and protein bands were visualized on an X-ray film
(GeneMate, Kaysville, UT, USA).
To measure Ras activity, pro-OBLs were deprived of serum
and growth factors for 24 h and then stimulated with PDGF
(20 ng/ml) for 2 min. Cells were lysed in nonionic lysis buffer
(20 mM Tris–Cl, 137 mM NaCl, 1 mM EGTA, 1% Triton
X-100, 10% glycerol, 1.5 mM MgCl2) containing protease inhi-
bitors (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The protein concentration of the lysates was normalized using
a BCA assay kit (Pierce, Rockford, IL , USA). Ras activity
was determined using a Ras activation assay kit (Millipore Cor-
poration, Temecula, CA, USA) (67). Briefly, GTP-bound Ras
levels were determined by incubating cell lysates with Raf-1
Ras-binding domain conjugated to agarose beads followed by
an immunoblot using an anti-Ras antibody (Millipore Corpor-
ation). Total Ras was also measured (Cell Signaling). Image J
was used to quantitate densitometry for all protein bands.
Real time reverse-transcriptase polymerase chain reaction
To evaluate the expression of OBL differentiation markers in
pro-OBLs, a quantitative real-time reverse-transcriptase
4826 Human Molecular Genetics, 2013, Vol. 22, No. 23
polymerase chain reaction (qRT-PCR) was performed. Briefly,
total RNA was extracted from differentiated WT and Nf12/2
pro-OBLs in the presence or absence of PD98059 (100 nM)
using the RNeasy mini kit (Qiagen, Valencia, CA, USA). Com-
plementary DNA (cDNA) was synthesized according to the
protocol and using reagents from the high-capacity cDNA
reverse transcription kit (Life Technologies, Grand Island,
NY, USA). A qRT-PCR was performed (100 ng RNA was
used for each reaction) using the Taqman Fast universal PCR
Master mix (2X) and Taqman murine primers Sp7 (osterix),
BGLAP (osteocalcin), and Gapdh (Life Technologies).
Statistical analysis
Two-tailed Student’s t-test and analysis of variancewere used to
evaluate statistical difference. P-values ,0.05 were considered
significant.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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